Further support for the potential therapeutic utility of HDAC inhibitors in prevention and/or reversal of chronic migraine is provided by a study in a rat model of MOH, that found two pan-HDAC inhibitors (panobinostat and givinostat) reduced expression of the genes coding for calcitonin gene-related peptide (CGRP) and its receptor subunit Receptor Activity Modifying Protein 1 (RAMP1), whose proteins are known to have key roles in migraine pathogenesis and MOH [36]. The gene discussed is RAMP1; the disease is migraine disorder.